Zydus Life Rises 1.5% as Unit Partners With Formycon for Keytruda Biosimilar in US, Canada

Shares of Zydus Lifesciences Ltd surged 1.5% to touch a day’s high of Rs 936.45 on 10th December, after the firm on Tuesday (9th December) said its wholly-owned subsidiary, Zydus Lifesciences Global FZE, UAE, had entered into a strategic partnership with Formycon AG for the exclusive licensing and supply of FYB206, a biosimilar of Keytruda (pembrolizumab), in the United States and Canada.

Under the agreement, Formycon AG will handle the development, registration, manufacturing, and supply of FYB206. Meanwhile, Zydus Lifesciences Global FZE will manage its commercialisation in the US and Canada.

The biologics licence application is expected to be submitted to the US FDA soon. It aims to make immunotherapy more affordable and accessible.

Dr Sharvil P Patel, MD of Zydus Lifesciences, said the partnership marks Zydus’ entry into the North American biosimilar market. They are starting with an immunotherapy product.

The collaboration complements Zydus’ proposed acquisition of Agenus Inc.’s California manufacturing facilities, which will be used for future production.

Combining expertise, the partnership aims to drive growth and expand patients’ access to affordable oncology care.

Dr Stefan Glombitza, CEO of Formycon, said the deal leverages both companies’ strengths. It aims to deliver this important biosimilar to patients in highly regulated markets.

At 1:15 PM, shares of Zydus Lifesciences were trading 0.76% higher at Rs 927.20 on NSE.

Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!

The post Zydus Life Rises 1.5% as Unit Partners With Formycon for Keytruda Biosimilar in US, Canada appeared first on Equitypandit.